# A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

> **NCT01456325** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 494 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Onartuzumab (MetMab)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01456325
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 494 (ACTUAL)
- **Last updated:** 2016-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01456325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01456325, "A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01456325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*